Former GC of Novo Nordisk Joins Lowenstein Sandler
Summary: The Life Sciences group at Lowenstein Sandler has added a notable former GC for Novo Nordisk as a senior counsel member.
Lowenstein Sandler LLP made the big announcement today of the addition of James Shehan to their team. Shehan is not only a talented attorney but a seasoned health care executive as well. He will fill the role as a senior counsel in the Life Science practice and as head of the FDA Regulatory Practice.
Shehan served as general counsel of Novo Nordisk for 19 years and most recently as counsel at Hyman, Phelps & McNamara, which is a FDA regulatory law boutique in Washington D.C. He also worked as corporate counsel at Pfizer and at the FDA early on his career.
“I’m excited to join my new Life Sciences colleagues at Lowenstein Sandler, who share my business-focused perspective on the industry and passion for helping clients bring new products to market,” Shehan said. “I admire the firm’s entrepreneurial approach and I share its enthusiasm to help clients innovate, develop, and commercialize lifesaving products.”
While Shehan was with Novo Nordisk, the company grew into a market leader in diabetes products with sales stretching from $100 million to over $5.5 billion. Under Shehan’s leadership, the legal, compliance and government staff grew to over 100 employees with a budget greater than $30 million.
The chair of Lowenstein’s Life Science group Michael J. Lerner said, “Jim’s impressive credentials will add value to our clients as we continue to expand our regulatory practice and provide counsel to companies on a wide variety of matters, including drug development and marketing, M&A, and compliance. His deep industry knowledge and extensive experience will enhance Lowenstein’s longstanding work with emerging and established life sciences companies, investors, and investment banks.”
He earned his J.D. from Georgetown University Law Center and his B.A. from Columbia University.